Amendments to the Claims

Please cancel claims 1-41 without prejudice to applicants' rights to pursue the subject matter of these claims in this or a related application. The pending claims in the subject application are presented below.

Claims 1-41. (Canceled)

42. (Original) A method for treating a subject afflicted with a disease associated with an A_1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:



or



or a pharmaceutically acceptable salt thereof so as to thereby treat the subject, wherein the disease is antidiuresis, bradycardia, bronchitis, bronchoconstriction, Alzheimer's disease, cardiac arrythmias, cardiac hypoxia, congestive heart failure, hypertension, inflammation, negative cardiac inotropy and dromotropy, renal failure, sedation or is associated with transmitter release, respiratory epithelia, contraction of smooth muscle underlying respiratory epithelia, vasoconstriction or mast cell degranulation.

43. (Original) The method of claim 42, wherein the subject is a mammal.

44. (Original) The method of claim 43, wherein the mammal is a human.

45. (Original) The method of claim 42, wherein the disease is congestive heart failure.

46. (Original) A method for inhibiting the activity of an A1 adenosine receptor in a cell, which comprises contacting the cell with a compound having the structure:



or



or a pharmaceutically acceptable salt thereof.

47. (Original) The method of claim 46, wherein the cell is a human cell.

48. (Original) A method for treating a subject having a respiratory disorder associated with the A1 adenosine receptor in need of such treatment, comprising administering to the subject a therapeutically effective amount of a compound having the structure:



or



or a pharmaceutically acceptable salt thereof, so as to thereby treat the subject.

49. (Original) The method of claim 48, wherein the respiratory disorder is asthma, chronic obstructive pulmonary disease, allergic rhinitis, or an upper respiratory disorder.

50. (Original) The method of claim 48, wherein the subject is a human.

51. (Original) A prodrug of a compound having the structure:



or



wherein the prodrug is metabolized *in vivo* by a human subject to an active drug which selectively inhibits the A1 adenosine receptor wherein the prodrug is

an N-Mannich base or an imine of an amine group; or

a Schiff base, oxime, acetal, enol ester, oxazolidine, or thiazolidine of a carbonyl group.

52. (Original) The prodrug of claim 51, wherein the prodrug is water-soluble.

53. (Original) A pharmaceutical composition comprising the prodrug of claim 51 and a pharmaceutically acceptable carrier.

54. (Original) A pharmaceutical composition comprising a compound having the structure:



or



or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

55. (Original) The pharmaceutical composition of claim 54, further comprising at least one of either a steroid, β2 agonist, glucocorticoid, leukotriene antagonist, or an anticolinergic agonist.

56. (Original) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for administration as a periocular, retrobulbar or intraocular injection.

57. (Original) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for systemic administration.

58. (Original) The pharmaceutical composition of claim 54, wherein the pharmaceutical composition is formulated for administration as a surgical irrigating solution.

59. (Original) A packaged pharmaceutical composition for treating a subject suffering from a disease associated with an A1 adenosine receptor, comprising the pharmaceutical

composition of claim 54 and instructions for using the composition for treating the subject.